AR058735A1 - Composiciones farmaceuticas que contienen la proteina nma 0939 - Google Patents
Composiciones farmaceuticas que contienen la proteina nma 0939Info
- Publication number
- AR058735A1 AR058735A1 ARP060105777A ARP060105777A AR058735A1 AR 058735 A1 AR058735 A1 AR 058735A1 AR P060105777 A ARP060105777 A AR P060105777A AR P060105777 A ARP060105777 A AR P060105777A AR 058735 A1 AR058735 A1 AR 058735A1
- Authority
- AR
- Argentina
- Prior art keywords
- nma0939
- protein
- compositions
- pharmaceutical compositions
- compositions containing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Analytical Chemistry (AREA)
- Communicable Diseases (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Composiciones farmacéuticas que contienen la proteína NMA0939. Las composiciones confieren proteccion contra diferentes enfermedades, causadas o no por patogenos. LA proteína NMA0939 se identifico como componente de las preparaciones de vesículas de membrana externa de Neisseria meningitidis, se obtuvo mediante la tecnología del ADN recombinante y se evaluo su inmunogenicidad y actividad protectora en modelos animales. Por el elevado grado de conservacion del gen que codifica para la proteína NMA0939, las composiciones que la contienen poseen alto valor como antígeno inductor de una respuesta inmune de amplia reactividad. Las composiciones son aplicables en la medicina humana.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20050279A CU23549A1 (es) | 2005-12-29 | 2005-12-29 | Composiciones farmacéuticas que contienen la proteína nma0939 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR058735A1 true AR058735A1 (es) | 2008-02-20 |
Family
ID=38218331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060105777A AR058735A1 (es) | 2005-12-29 | 2006-12-26 | Composiciones farmaceuticas que contienen la proteina nma 0939 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20090208521A1 (es) |
| EP (1) | EP1977761A2 (es) |
| KR (1) | KR20080081198A (es) |
| CN (1) | CN101443037A (es) |
| AR (1) | AR058735A1 (es) |
| AU (1) | AU2006331224A1 (es) |
| BR (1) | BRPI0620867A2 (es) |
| CA (1) | CA2633424A1 (es) |
| CU (1) | CU23549A1 (es) |
| NO (1) | NO20083318L (es) |
| RU (1) | RU2008131066A (es) |
| WO (1) | WO2007073705A2 (es) |
| ZA (1) | ZA200805355B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12109259B2 (en) | 2016-09-02 | 2024-10-08 | Glaxosmithkline Biologicals Sa | Vaccines for Neisseria gonorrhoeae |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0010361A (pt) * | 1999-04-30 | 2003-06-10 | Chiron Corp | Seq ências genÈmicas de neisseria e uso destas |
| GB0103424D0 (en) * | 2001-02-12 | 2001-03-28 | Chiron Spa | Gonococcus proteins |
| WO2004015099A2 (en) * | 2002-08-02 | 2004-02-19 | Glaxosmithkline Biologicals Sa | Vaccine composition comprising lipooligosaccharide with reduced phase variability |
| CU23236A1 (es) * | 2003-12-03 | 2007-09-26 | Ct Ingenieria Genetica Biotech | PROTEINA NMB0928 Y SU USO EN FORMULACIONES FARMACéUTICAS P |
-
2005
- 2005-12-29 CU CU20050279A patent/CU23549A1/es active IP Right Grant
-
2006
- 2006-12-26 AR ARP060105777A patent/AR058735A1/es unknown
- 2006-12-28 BR BRPI0620867-3A patent/BRPI0620867A2/pt not_active IP Right Cessation
- 2006-12-28 RU RU2008131066/13A patent/RU2008131066A/ru not_active Application Discontinuation
- 2006-12-28 CN CNA200680049521XA patent/CN101443037A/zh active Pending
- 2006-12-28 WO PCT/CU2006/000019 patent/WO2007073705A2/es active Search and Examination
- 2006-12-28 CA CA002633424A patent/CA2633424A1/en not_active Abandoned
- 2006-12-28 EP EP06846929A patent/EP1977761A2/en not_active Withdrawn
- 2006-12-28 KR KR1020087018520A patent/KR20080081198A/ko not_active Application Discontinuation
- 2006-12-28 AU AU2006331224A patent/AU2006331224A1/en not_active Abandoned
- 2006-12-28 US US12/097,895 patent/US20090208521A1/en not_active Abandoned
-
2008
- 2008-06-19 ZA ZA200805355A patent/ZA200805355B/xx unknown
- 2008-07-28 NO NO20083318A patent/NO20083318L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007073705A3 (es) | 2007-09-13 |
| CA2633424A1 (en) | 2007-07-05 |
| KR20080081198A (ko) | 2008-09-08 |
| CU23549A1 (es) | 2010-07-20 |
| NO20083318L (no) | 2008-09-26 |
| ZA200805355B (en) | 2009-04-29 |
| CU23549B7 (es) | 2010-07-20 |
| RU2008131066A (ru) | 2010-02-10 |
| US20090208521A1 (en) | 2009-08-20 |
| EP1977761A2 (en) | 2008-10-08 |
| AU2006331224A1 (en) | 2007-07-05 |
| WO2007073705A2 (es) | 2007-07-05 |
| CN101443037A (zh) | 2009-05-27 |
| BRPI0620867A2 (pt) | 2011-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021002586A (es) | Dosis unitaria de vacuna contra el dengue y administracion de esta. | |
| NO20073868L (no) | Levende attenuert rotavirus vaksine for oral administrering | |
| CO7010783A2 (es) | Proteína naglu humana recombinante y usos de la misma | |
| BRPI0416796A (pt) | compostos orgánicos | |
| WO2015024667A8 (en) | Method for increasing expression of rna-encoded proteins | |
| CY1113570T1 (el) | Μυκητοκτονες συνθεσεις | |
| NZ601538A (en) | Vaccine compositions comprising a mutated factor h binding protein | |
| WO2008124646A3 (en) | Use of amyloid proteins as vaccine scaffolds | |
| ATE461710T1 (de) | Nipah-virus-impfstoffe | |
| CY1113693T1 (el) | Φαρμακευτικες συνθεσεις και μεθοδοι για τον εμβολιασμο κατα της διαχυτης καντιντιασης και αλλων μολυσματικων παραγοντων | |
| GEP201706766B (en) | Methods and compositions for vaccinating against staphylococcus aureus | |
| EA202090319A1 (ru) | Пептидные конъюгаты, способ конъюгации и их использование | |
| BR112015012057A2 (pt) | misturas binárias fungicidas | |
| AR058735A1 (es) | Composiciones farmaceuticas que contienen la proteina nma 0939 | |
| WO2007008904A3 (en) | Targeting poly-gamma-glutamic acid to treat staphylococcus epidermidis and related infections | |
| CU23572A1 (es) | Composición farmacéutica que comprende la proteína nmb0938 | |
| WO2009077744A3 (en) | Vaccines for brucellosis | |
| WO2010080188A3 (en) | Epitope targeted anthrax vaccine | |
| AR060797A1 (es) | Composicion farmaceutica que comprende la proteina nmb0606 | |
| CU23528A1 (es) | Composición farmacéutica que comprende la proteína nmb0848 | |
| CU23584A1 (es) | Composición farmacéutica que comprende la proteína nmb1796 | |
| MX2022001742A (es) | Metodos para prevenir el dengue y la hepatitis a. | |
| AR046937A1 (es) | Proteina nmb0928 y su uso en formulaciones farmaceuticas | |
| NZ591738A (en) | Non-typhoidal salmonella vaccines comprising a polypeptide which is an outer membrane protein d of non typoidal salmonella | |
| AR047263A1 (es) | Proteina nmb1125 y su uso en formulaciones farmaceuticas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |